Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .
Effect of gemfibrozil treatment in sulfonylurea-treated patients with noninsulin-dependent diabetes mellitus.
This study was initiated to 1 ) assess gemfibrozil 's ability to lower plasma triglyceride ( TG ) concentration in patients with NIDDM , and 2 ) determine whether this effect was associated with any changes in glycemic control . Measurements were made of mean hourly plasma glucose , insulin , TG , and FFA concentrations from 1200 - 1600 h in response to a test meal ; hepatic glucose production ( HGP ) ; insulin-stimulated glucose uptake during a hyperinsulinemic glucose clamp study ( MCR ) ; and fasting plasma lipoprotein TG and cholesterol concentrations in 12 patients with NIDDM before and 3 months after gemfibrozil treatment . Although ambient plasma TG and FFA concentrations fell significantly , plasma glucose , insulin , HGP , concentrations fell significantly , plasma glucose , insulin , HGP , and glucose MCR did not change . However , when patients were divided into two groups , those with fasting plasma glucose levels above 9 mmol/L ( fair control ) and those with levels below 9 mmol/L ( good control ) , a different phenomenon was observed . Patients in fair control had significant decreases in mean hourly plasma concentrations of glucose ( 15.1 + /- 1.7 to 12.6 + /- 0.9 mmol/L ; P less than 0.001 ) , insulin ( 523 + /- 59 to 471 + /- 75 pmol/L ; P less than 0.001 ) , FFA ( 652 + /- 150 to 504 + /- 76 mumol/L ) , and HGP ( 9.5 0.4 to 8.1 + /- 0.4 mumol/kg.min ; P less than 0.005 ) , and an increase in glucose MCR ( 2.63 + /- 0.49 to 3.72 + /- 0.54 mL/kg.min ; P less than 0.07 ) in association with a fall in TG from 6.9 + /- 1.3 to 3.5 + /- 0.9 mmol/L ( P less than 0.001 ) . Although fasting low density lipoprotein cholesterol increased ( 1.8 + /- 0.2 to 2.7 + /- 0.2 mmol/L ; P less than 0.05 ) , the ratio of total to high density lipoprotein cholesterol decreased ( 6.84 + /- 0.88 to 5.80 + /- 1.05 ; P less than 0.02 ) . Despite a significant fall in mean hourly TG concentration ( 4.6 + /- 0.7 to 3.8 + /- 0.7 mmol/L ; P less than 0.001 ) , neither insulin , FFA , HGP , nor glucose MCR changed in patients in good control . Furthermore , the mean hourly plasma glucose concentration increased from 9.2 + /- 0.7 to 11.7 + /- 1.4 mmol/L ( P less than 0.001 ) . Low density lipoprotein cholesterol also increased in this group ( 1.9 + /- 0.2 to 2.7 + /- 0.2 mmol/L ; P less than 0.02 ) , but , as before , the ratio of total to high density lipoprotein cholesterol decreased ( 8.15 + /- 1.93 to 6.36 + /- 1.03 ; P less than 0.02 )
Conclusion : This meta‐ analysis has shown that fibrate treatment  significantly decreases fasting plasma glucose , insulin levels , and HOMA‐IR indicating additional clinical therapeutic benefits .
Aims : The aim of this meta‐ analysis of r and omized placebo‐controlled clinical trials was to assess the effect of fibrates on glycemic parameters .